Biohaven's IgG Degrader Takes on Graves' Disease in First Phase 3 Trial of This Novel Antibody-Depleting Approach

BHV-1300 targets the autoantibody root cause of Graves' hyperthyroidism — asking whether patients can reach normal thyroid function without antithyroid drugs by Week 26.

Biohaven Therapeutics has registered the first Phase 3 trial of a MoDE (Modular Degradation Engine) IgG degrader designed to treat Graves’ hyperthyroidism, signaling a potential pivot away from a treatment landscape that has changed little in decades.

The study — a double-blind, multicenter, randomized, placebo-controlled trial — will enroll 300 adults aged 18 to 70 with serologically confirmed, actively hyperthyroid Graves’ disease. Participants cannot have prior radioactive iodine (RAI) treatment or thyroid surgery, making this a first-line biologics test in treatment-naïve patients (NCT07661056).

The mechanism

BHV-1300 is a MoDE (Modular Degradation Engine) small-molecule IgG degrader — a mechanistic class Biohaven explicitly distinguishes from FcRn inhibitors. Rather than blocking the neonatal Fc receptor that recycles IgG antibodies, BHV-1300 routes IgG toward degradation through a separate pathway, without interacting with FcRn. By depleting IgG, the drug reduces all IgG subclasses — including TSH receptor antibodies (TRAb), the autoantibodies that drive hyperthyroidism in Graves’ disease. The hypothesis: deplete TRAb fast enough and the thyroid quiets down without lifelong drug dependence.

What the trial is measuring

The primary endpoint is the number of participants who are off antithyroid drugs (ATD) with normal Total T3, free T4, and TSH at Week 26 — a composite euthyroidism-off-treatment bar. Pre-specified secondary endpoints include: TRAb (TBII) change from baseline at Weeks 6 and 26; total IgG change at Weeks 6 and 26; proportion off ATD with normal Total T3 and free T4 at Week 26; time to normal thyroid hormones off ATD; time to euthyroidism off ATD; TRAb seronegativity at Week 26; and the composite of euthyroid, off ATD, and TRAb seronegative at Week 26. Safety secondaries track serious adverse events, Grade 3/4 lab abnormalities, and discontinuations.

Standard options — ATDs, RAI, thyroidectomy — carry well-known trade-offs: high ATD relapse rates, permanent hypothyroidism after ablation, and surgical risk. An IgG-depleting strategy that eliminates the causative autoantibody could offer durable remission without those consequences, though that claim remains unproven at this scale.

The trial is slated to begin enrolling in June 2026, with primary completion estimated in January 2028. BHV-1300 is investigational and not approved for any indication.

Correction — June 23, 2026: Two critical errors have been corrected in this article. (1) The headline and body originally described BHV-1300 as an “FcRn Blocker” and “FcRn inhibitor.” BHV-1300 is a MoDE (Modular Degradation Engine) small-molecule IgG degrader that, per Biohaven, does not interact with FcRn; the mechanism section has been rewritten accordingly. (2) The original text stated this was “the first Phase 3 trial of an FcRn inhibitor specifically designed to treat Graves’ hyperthyroidism.” This claim was wrong on two counts: BHV-1300 is not an FcRn inhibitor, and prior FcRn inhibitor trials for Graves’ disease exist (including a batoclimab Phase 2 proof-of-concept study and an IMVT-1402 extension study). The article now accurately describes BHV-1300 as the first Phase 3 trial of a MoDE IgG degrader for Graves’ hyperthyroidism.

Trace · every claim, sourced

Reported and written by Dr. Priya Raman, Clinical Trials Desk, then each load-bearing claim was bound to the primary source it rests on and checked out-of-band against that source before publication. The full mapping is below — nothing here is taken on faith.

The trial is a Phase 3, double-blind, multicenter, randomized, placebo-controlled study of BHV-1300 in adults with Graves' disease (NCT07661056).

trial_registry Phase 3 of BHV-1300 in Graves' Disease — ClinicalTrials.gov NCT07661056

Planned enrollment is 300 participants, aged 18 to 70 years.

trial_registry Phase 3 of BHV-1300 in Graves' Disease — ClinicalTrials.gov NCT07661056

The primary endpoint is the number of participants not on ATD with normal Total T3, free T4, and TSH at Week 26.

trial_registry Phase 3 of BHV-1300 in Graves' Disease — ClinicalTrials.gov NCT07661056

Estimated start date is June 2026; primary completion date is January 2028.

trial_registry Phase 3 of BHV-1300 in Graves' Disease — ClinicalTrials.gov NCT07661056

BHV-1300 is investigational and not approved for any indication.

trial_registry Phase 3 of BHV-1300 in Graves' Disease — ClinicalTrials.gov NCT07661056

After publication, a separate AI panel re-verifies every edition against these same sources. The running claim-confirmation rate and every correction are public on the accuracy ledger.